Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John A Wells

Showing results (11-20 of 38) with videos related to

Pageof 4
Sort By:
JAMA Ophthalmology|October 7, 2016
Anti-Vascular Endothelial Growth Factor Comparative Effectiveness Trial for Diabetic Macular Edema: Additional Efficacy Post Hoc Analyses of a Randomized Clinical TrialLee M Jampol, Adam R Glassman, Neil M Bressler, et al.
Ophthalmic Surgery, Lasers & Imaging Retina|May 18, 2018
A Phase 1, Open-Label, Dose-Escalation Trial to Investigate Safety and Tolerability of Single Intravitreous Injections of ICON-1 Targeting Tissue Factor in Wet AMDJohn A Wells, Christine R Gonzales, Brian B Berger, et al.
Archives of Ophthalmology (Chicago, Ill. : 1960)|September 12, 2012
Factors associated with changes in visual acuity and central subfield thickness at 1 year after treatment for diabetic macular edema with ranibizumabSusan B Bressler, Haijing Qin, Roy W Beck, et al.
Neurosurgery|June 22, 2013
Comprehensive assessment of 1-year outcomes and determination of minimum clinically important difference in pain, disability, and quality of life after suboccipital decompression for Chiari malformation I in adultsScott L Parker, Saniya S Godil, Scott L Zuckerman, et al.
JAMA Ophthalmology|February 3, 2018
Persistent Macular Thickening Following Intravitreous Aflibercept, Bevacizumab, or Ranibizumab for Central-Involved Diabetic Macular Edema With Vision Impairment: A Secondary Analysis of a Randomized Clinical TrialNeil M Bressler, Wesley T Beaulieu, Adam R Glassman, et al.
Ophthalmology|March 12, 2018
Plasma Vascular Endothelial Growth Factor Concentrations after Intravitreous Anti-Vascular Endothelial Growth Factor Therapy for Diabetic Macular EdemaLee M Jampol, Adam R Glassman, Danni Liu, et al.
Archives of Ophthalmology (Chicago, Ill. : 1960)|April 15, 2009
Pegaptanib sodium for macular edema secondary to central retinal vein occlusionJohn J Wroblewski, John A Wells, Anthony P Adamis, et al.
Ophthalmology Science|October 17, 2022
Phase 1 Study of THR-687, a Novel, Highly Potent Integrin Antagonist for the Treatment of Diabetic Macular EdemaArshad M Khanani, Sunil S Patel, Victor H Gonzalez, et al.
Ophthalmology. Retina|December 8, 2019
One-Time Intravitreal Injection of KVD001, a Plasma Kallikrein Inhibitor, in Patients with Central-Involved Diabetic Macular Edema and Reduced Vision: An Open-Label Phase 1B StudyJennifer K Sun, Raj K Maturi, David S Boyer, et al.
JAMA Ophthalmology|April 28, 2017
Change in Diabetic Retinopathy Through 2 Years: Secondary Analysis of a Randomized Clinical Trial Comparing Aflibercept, Bevacizumab, and RanibizumabSusan B Bressler, Danni Liu, Adam R Glassman, et al.
Pageof 4

Showing results (11-20 of 38) with videos related to

Sort By:
Pageof 4
JAMA Ophthalmology|October 7, 2016
Anti-Vascular Endothelial Growth Factor Comparative Effectiveness Trial for Diabetic Macular Edema: Additional Efficacy Post Hoc Analyses of a Randomized Clinical TrialLee M Jampol, Adam R Glassman, Neil M Bressler, et al.
Ophthalmic Surgery, Lasers & Imaging Retina|May 18, 2018
A Phase 1, Open-Label, Dose-Escalation Trial to Investigate Safety and Tolerability of Single Intravitreous Injections of ICON-1 Targeting Tissue Factor in Wet AMDJohn A Wells, Christine R Gonzales, Brian B Berger, et al.
Archives of Ophthalmology (Chicago, Ill. : 1960)|September 12, 2012
Factors associated with changes in visual acuity and central subfield thickness at 1 year after treatment for diabetic macular edema with ranibizumabSusan B Bressler, Haijing Qin, Roy W Beck, et al.
Neurosurgery|June 22, 2013
Comprehensive assessment of 1-year outcomes and determination of minimum clinically important difference in pain, disability, and quality of life after suboccipital decompression for Chiari malformation I in adultsScott L Parker, Saniya S Godil, Scott L Zuckerman, et al.
JAMA Ophthalmology|February 3, 2018
Persistent Macular Thickening Following Intravitreous Aflibercept, Bevacizumab, or Ranibizumab for Central-Involved Diabetic Macular Edema With Vision Impairment: A Secondary Analysis of a Randomized Clinical TrialNeil M Bressler, Wesley T Beaulieu, Adam R Glassman, et al.
Ophthalmology|March 12, 2018
Plasma Vascular Endothelial Growth Factor Concentrations after Intravitreous Anti-Vascular Endothelial Growth Factor Therapy for Diabetic Macular EdemaLee M Jampol, Adam R Glassman, Danni Liu, et al.
Archives of Ophthalmology (Chicago, Ill. : 1960)|April 15, 2009
Pegaptanib sodium for macular edema secondary to central retinal vein occlusionJohn J Wroblewski, John A Wells, Anthony P Adamis, et al.
Ophthalmology Science|October 17, 2022
Phase 1 Study of THR-687, a Novel, Highly Potent Integrin Antagonist for the Treatment of Diabetic Macular EdemaArshad M Khanani, Sunil S Patel, Victor H Gonzalez, et al.
Ophthalmology. Retina|December 8, 2019
One-Time Intravitreal Injection of KVD001, a Plasma Kallikrein Inhibitor, in Patients with Central-Involved Diabetic Macular Edema and Reduced Vision: An Open-Label Phase 1B StudyJennifer K Sun, Raj K Maturi, David S Boyer, et al.
JAMA Ophthalmology|April 28, 2017
Change in Diabetic Retinopathy Through 2 Years: Secondary Analysis of a Randomized Clinical Trial Comparing Aflibercept, Bevacizumab, and RanibizumabSusan B Bressler, Danni Liu, Adam R Glassman, et al.
Pageof 4